Fig. 1From: Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENTDifferences in the ASAS40 response between secukinumab and placebo at week 16. A MRI and CRP status. B HLA-B27 status. C sex at screening. ASAS, Assessment of SpondyloArthritis international Society; CRP, C-reactive protein; HLA, human leukocyte antigen; M, number of evaluable patients; MRI, magnetic resonance imagingBack to article page